Diseases of the Neuromuscular Junction

Slide 1 · Diseases of the

Neuromuscular Junction

From synaptic mechanism to clinicopathologic diagnosis

Autoimmune • Inherited • Toxin mediated

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Explain how the normal motor nerve terminal activates a skeletal myofiber.

Localize defects to presynaptic, synaptic or postsynaptic components.

Differentiate autoimmune, inherited and toxin-associated junction disorders.

Connect characteristic weakness patterns with underlying transmission defects.

Slide 3 · The junction links motor axons and muscle

A specialized interface between the distal motor axon and a skeletal myofiber.

Motor axon depolarization is converted into a muscle-contraction signal.

A functional disturbance produces weakness without requiring primary muscle-fiber injury.

Functional site schematic

Motor-axon terminal

Synaptic cleft

Myofiber sarcolemma

Normal transmission → muscle activation

Slide 4 · One motor axon branches into terminal boutons

Distal motor axon

Multiple smaller terminal branches

Bulbous synaptic boutons on innervated myofibers

Interpretation

A motor unit comprises a motor neuron and the muscle fibers it supplies.

Each bouton delivers transmitter close to the sarcolemma.

Slide 5 · Three compartments form the junction

Compartment

Key anatomical feature

Functional role

Presynaptic terminal

Motor-axon bouton

Releases acetylcholine

Synaptic cleft

Space between membranes

Allows transmitter to diffuse

Postsynaptic membrane

Folded sarcolemma with clustered receptors

Initiates the muscle response

Slide 6 · Synaptic release follows nerve depolarization

Motor-axon depolarization

Presynaptic ACh release

ACh enters the synaptic cleft

Transmitter reaches muscle receptors

Interpretation

The presynaptic bouton is the release site.

Defects at this step compromise the supply of transmitter.

Slide 7 · Postsynaptic folds concentrate receptor sites

The muscle sarcolemma is extensively infolded at the junction.

Acetylcholine receptors are clustered in the specialized postsynaptic membrane.

Receptor organization is essential to effective signaling.

Functional site schematic

Motor-axon terminal

Synaptic cleft

Myofiber sarcolemma

Clustered postsynaptic receptors

Slide 8 · Acetylcholine initiates the muscle response

ACh released from the nerve terminal

ACh receptor activation on sarcolemma

Postsynaptic signal generation

Initiation of contraction

Interpretation

The receptor-bearing membrane converts chemical transmission into muscle activation.

A low effective receptor response causes weakness.

Slide 9 · Neuromuscular transmission is a multistep process

Nerve terminal

Release ACh

Synaptic cleft

Deliver transmitter

Muscle membrane

Activate clustered ACh receptors

Myofiber

Generate contraction signal

Slide 10 · Failure at distinct sites can produce weakness

Site of defect

Representative mechanism

Textbook example

Presynaptic release

Autoantibody / toxin decreases ACh release

Lambert–Eaton; botulinum toxin

Postsynaptic function

Autoantibodies impair receptors or clustering

Myasthenia gravis

Junction protein

Inherited functional abnormality

Congenital myasthenic syndromes

Postsynaptic blockade

Direct interference with ACh receptors

Curare

Slide 11 · Painless weakness is the shared phenotype

Different causal mechanisms converge on ineffective neuromuscular transmission.

Patients commonly describe weakness and fatigue without pain.

A fluctuating or activity-dependent pattern can help separate junction disorders from primary myopathy.

Slide 12 · The etiologic framework has three major groups

Disease group

Biologic origin

Examples

Acquired immune mediated

Autoantibodies recognize junction proteins

Myasthenia gravis; Lambert–Eaton

Inherited

Variants in genes for junction proteins

Congenital myasthenic syndromes

Toxin associated

Exogenous blockade of transmission

Botulinum toxin; curare

Slide 13 · Localizing the lesion explains clinical behavior

Presynaptic

Transmitter release is the defective step.

ACh reaching muscle may increase with repeated activity in Lambert–Eaton.

Botulinum toxin also affects release.

Postsynaptic

Receptor availability or organization is reduced.

ACh receptor antibodies and MuSK antibodies impair this interface.

Curare blocks ACh receptors.

Slide 14 · Myasthenia gravis is receptor-directed autoimmunity

An autoimmune myasthenic disease, usually involving antibodies against postsynaptic ACh receptors.

The final common effect is a reduced muscle response to released acetylcholine.

The disorder characteristically causes fluctuating weakness.

Functional site schematic

Motor-axon terminal

Synaptic cleft

Myofiber sarcolemma

Reduced functional ACh receptors

Slide 15 · The epidemiology of myasthenia gravis is bimodal

Textbook descriptor

Reported finding

Prevalence

150–200 per million

Age pattern

Bimodal distribution

Young adults

Female-to-male ratio approximately 2:1

Older adults

Male predominance

Slide 16 · Two major antibody targets dominate the disease

Antibody target

Frequency / context

Functional consequence

ACh receptor

About 85% of patients

Receptor depletion and membrane damage

Muscle-specific kinase (MuSK)

Most of the remainder

Impaired ACh-receptor organization

Slide 17 · ACh-receptor antibodies promote receptor loss

Anti–ACh receptor antibodies

Receptor aggregation and degradation

Fewer functional surface receptors

Reduced response to released ACh

Interpretation

The source describes antibody-driven receptor aggregation and degradation.

This process reduces the postsynaptic signaling capacity.

Slide 18 · Complement injury compounds receptor depletion

Anti–ACh receptor antibodies

Complement fixation on postsynaptic surface

Postsynaptic membrane damage

Less effective neuromuscular transmission

Interpretation

Complement-mediated damage is a separate important mechanism.

Structural injury accompanies loss of surface receptors.

Slide 19 · The postsynaptic membrane becomes functionally depleted

The altered postsynaptic membrane has reduced ACh-receptor content.

Even normally released ACh generates a smaller effective response.

The anatomic and molecular lesions explain muscle fatigue.

Functional site schematic

Motor-axon terminal

Synaptic cleft

Myofiber sarcolemma

Reduced functional ACh receptors

Slide 20 · MuSK antibodies disrupt receptor clustering

Anti-MuSK antibodies

Interference with receptor trafficking / clustering

Disorganized postsynaptic ACh receptors

Decreased effective receptor signaling

Interpretation

MuSK is a sarcolemmal receptor tyrosine kinase.

This antibody effect differs from the complement-fixing ACh-receptor mechanism.

Slide 21 · ACh receptor and MuSK disease differ mechanistically

Feature

ACh receptor antibodies

MuSK antibodies

Main target

Postsynaptic ACh receptor

Muscle-specific receptor tyrosine kinase

Described mechanism

Receptor loss and complement damage

Impaired trafficking / clustering

Complement fixation

Mechanistic contributor

Not described as complement fixing

Shared consequence

Reduced effective ACh response

Reduced effective ACh response

Slide 22 · Evidence supports autoantibody pathogenicity

Patient serum contains autoantibodies

Disease can be transferred to experimental animals

Lowering autoantibody levels improves symptoms

Autoantibodies are a causal disease mechanism

Interpretation

These observations link antibodies with clinical weakness.

The mechanistic evidence supports immunomodulatory treatment.

Slide 23 · The thymus is linked to ACh-receptor autoimmunity

Thymic abnormalities are strongly associated with anti–ACh receptor myasthenia gravis.

Both thymoma and follicular thymic hyperplasia occur in affected patients.

The source proposes disturbed immune tolerance as a unifying explanation.

Slide 24 · A subset of patients has thymoma

Approximately 10% of patients with myasthenia gravis have thymoma.

Thymoma is a tumor derived from thymic epithelial cells.

The tumor provides an important clinicopathologic association, not a universal finding.

Slide 25 · Thymic hyperplasia includes B-cell follicles

An additional approximately 30% show thymic hyperplasia, particularly younger patients.

Hyperplastic thymus may contain prominent B-cell follicles.

This finding highlights a potential site of dysregulated immune responses.

Slide 26 · Disrupted thymic self-tolerance is a hypothesis

Thymus normally expresses peripheral tissue antigens

Thymoma / hyperplasia may disturb antigen expression

Failure of self-tolerance is hypothesized

Autoimmunity against ACh receptors

Interpretation

The book explicitly presents this causal link as a hypothesis.

Do not interpret thymic pathology as proven necessary for disease.

Slide 27 · Older-onset cases often lack thymic pathology

Younger patients

Thymic hyperplasia is particularly common.

B-cell follicles can accompany hyperplasia.

Thymic antigen expression is a possible contributor.

Older patients

Thymic abnormalities are usually absent.

The basis for autoantibody formation may remain unclear.

Absence of a lesion does not exclude myasthenia gravis.

Slide 28 · Fluctuating weakness is a diagnostic clue

Use or exertion

Weakness becomes more prominent

Symptoms may worsen over the day

Reduced motor performance

Interpretation

The history often reveals variability rather than fixed deficit.

Consider the time course as well as the affected muscles.

Slide 29 · Ocular muscles are frequently affected

Ptosis and diplopia are characteristic presenting manifestations.

Extraocular muscle involvement helps distinguish myasthenia gravis from many myopathies.

Weakness can remain restricted to the ocular muscles.

Slide 30 · The phenotype ranges from ocular to generalized

Distribution

Clinical implication

Ocular-limited involvement

Ptosis and diplopia dominate

Generalized involvement

Additional skeletal muscle groups weaken

Severe generalized disease

Respiratory muscle weakness may require mechanical ventilation

Slide 31 · Respiratory involvement can be life-threatening

Some patients develop sufficiently severe generalized weakness to impair breathing.

Mechanical ventilation may be required.

Recognizing weakness involving respiration is an important clinical priority.

Slide 32 · MuSK-associated symptoms have a distinct emphasis

Muscle regions

Described involvement

Neck / shoulder

Relatively focal weakness may predominate

Face / bulbar muscles

Characteristic involvement

Respiratory muscles

Potentially prominent weakness

Slide 33 · Diagnosis integrates four information sources

History

Fluctuation and exertional change

Examination

Distribution of weakness

Serology

Relevant autoantibody identification

Electrophysiology

Repeated-stimulation response

Slide 34 · Repeated stimulation reveals decrement in myasthenia

Repeated nerve stimulation

Sequential muscle responses

Responses decrease with repetitions

Physiologic support for MG

Interpretation

The source identifies declining responses as characteristic.

This is distinct from the increase described in Lambert–Eaton syndrome.

Slide 35 · Acetylcholinesterase inhibitors prolong ACh action

Acetylcholinesterase inhibition

ACh persists longer in the cleft

More opportunity for postsynaptic receptor activation

Improved transmission and strength

Interpretation

The text identifies these drugs as first-line treatment.

Treatment addresses transmitter availability, not antibody production.

Slide 36 · Reducing autoantibody burden can control symptoms

Therapeutic approach

Mechanistic goal

Plasmapheresis

Reduce circulating pathogenic antibodies

Immunosuppressive therapy

Limit autoimmune disease activity

Accelerated IgG catabolism

Lower antibody levels

Slide 37 · Complement-directed treatment targets tissue injury

Anti–ACh receptor antibodies

Complement-mediated postsynaptic damage

Complement pathway inhibition

Less complement-mediated injury

Interpretation

New complement-targeted therapies.

This treatment target provides additional support for complement involvement.

Slide 38 · Thymectomy depends on thymic context

Setting

Textbook statement

Associated thymoma

Often effective

Thymic hyperplasia

Benefit described as uncertain

No thymic abnormality

Benefit described as uncertain

Slide 39 · MG outcomes improved with modern treatment

The book contrasts historical mortality exceeding 30% in the 1950s with less than 5% under contemporary therapy.

Improved outcomes reflect the availability of treatments addressing transmission and autoimmunity.

These are textbook historical comparisons, not a newly analyzed contemporary cohort.

Slide 40 · Lambert–Eaton targets presynaptic calcium channels

An autoimmune disorder mediated by antibodies that inhibit presynaptic calcium channels.

Reduced presynaptic acetylcholine release is the central functional defect.

This target lies on the opposite side of the junction from ACh-receptor myasthenia.

Functional site schematic

Motor-axon terminal

Synaptic cleft

Myofiber sarcolemma

Presynaptic calcium-channel inhibition

Slide 41 · Presynaptic blockade reduces transmitter output

Antibodies inhibit a presynaptic calcium channel

ACh release decreases

Less transmitter reaches muscle receptors

Neuromuscular transmission is impaired

Slide 42 · Brief activity may improve Lambert–Eaton strength

Initial muscle weakness

A few seconds of muscle activity

A transient augmentation of strength

Facilitation supports a presynaptic lesion

Interpretation

This contrast with myasthenia gravis is clinically informative.

The source reports augmentation, without supplying a numeric threshold.

Slide 43 · Electrical responses increase with rapid stimulation

Myasthenia gravis

Repeated stimulation causes a decrease in muscle response.

Weakness tends to worsen with exertion.

Postsynaptic transmission is compromised.

Lambert–Eaton

Rapid repetitive stimulation increases response.

Brief activity can augment strength.

ACh release is compromised presynaptically.

Slide 44 · Limb weakness is the typical Lambert–Eaton presentation

Patients typically present with weakness involving the extremities.

The physiologic hallmark is transient strengthening with a short period of activity.

This combination helps distinguish Lambert–Eaton from the common ocular-predominant myasthenic presentation.

Slide 45 · Approximately half of cases have associated cancer

The book reports an underlying malignancy in about half of Lambert–Eaton cases.

Small cell carcinoma of the lung is the most frequent associated tumor.

Junction-related symptoms can precede the cancer diagnosis, sometimes by years.

Slide 46 · Tumor-related antigen expression may drive autoimmunity

Neoplastic cells may express the calcium-channel antigen

An immune response recognizes the shared antigen

Autoantibodies also act at motor nerve terminals

Presynaptic ACh release declines

Interpretation

This proposed paraneoplastic mechanism is stated as a hypothesis.

The patient may present before the tumor becomes clinically recognized.

Slide 47 · Non-neoplastic Lambert–Eaton often coexists with autoimmunity

Not all Lambert–Eaton cases are associated with malignancy.

Patients without cancer may have additional autoimmune disease.

The textbook gives vitiligo and thyroid disease as examples.

Slide 48 · Lambert–Eaton therapy addresses release and autoimmunity

Treatment principle

Reason

Increase ACh release

Compensates for reduced presynaptic transmitter output

Immunosuppression

Reduces autoimmune activity

Slide 49 · MG versus Lambert–Eaton: Lesion localization

Diagnostic dimension

Myasthenia gravis

Lambert–Eaton

Autoantibody site

Postsynaptic receptors / MuSK

Presynaptic calcium channel

Principal consequence

Less effective postsynaptic response

Reduced ACh release

Repeated stimulation

Decrement

Increment

Activity effect

Often fatigability

Brief facilitation

Slide 50 · MG versus Lambert–Eaton: Clinical associations

Clinical dimension

Myasthenia gravis

Lambert–Eaton

Typical muscles

Common ocular involvement

Extremity weakness

Notable associated lesion

Thymoma / thymic hyperplasia

Often small cell lung carcinoma

Potential serious complication

Respiratory weakness

Underlying malignancy

Etiology

Autoimmune

Autoimmune; often paraneoplastic

Slide 51 · Congenital myasthenic syndromes are inherited

These rare disorders arise from inherited defects in neuromuscular-junction proteins.

Autosomal recessive inheritance is the most common pattern reported.

Variable molecular defects produce diverse degrees and patterns of weakness.

Slide 52 · Inherited abnormalities span the entire junction

Presynaptic proteins

Inherited release-pathway defects

Synaptic proteins

Inherited cleft-related defects

Postsynaptic proteins

Inherited receptor / clustering defects

Slide 53 · ACh-receptor ε-subunit loss of function is prominent

Variant in ACh receptor ε-subunit gene

Reduced receptor subunit function

Impaired neuromuscular transmission

Congenital weakness phenotype

Interpretation

The source identifies this as the most common molecular category.

The Markdown renders the Greek ε as “e”; Notation is normalized here.

Slide 54 · Genetic receptor-clustering defects form another group

Inherited defect in a clustering-associated protein

Abnormal ACh receptor localization

Less efficient postsynaptic activation

Variable muscle weakness

Slide 55 · Clinical onset may be perinatal or delayed

Onset pattern

Features reported

Perinatal

Poor muscle tone

Early ocular involvement

External eye muscle weakness

Breathing involvement

Respiratory difficulty

Later onset

Milder disease may appear in adolescence or adulthood

Slide 56 · Clinical response depends on the causal mutation

The underlying molecular defect influences symptom pattern and severity.

Response to acetylcholinesterase inhibitors differs among congenital syndromes.

Prognosis is likewise genotype dependent; A universal therapeutic response should not be assumed.

Slide 57 · Toxins disrupt normal synaptic transmission

Agent

Site of action

Effect

Botulinum neurotoxin

Presynaptic release mechanism

Prevents ACh release

Curare

Postsynaptic ACh receptor

Blocks ACh receptors

Slide 58 · Botulinum toxin prevents acetylcholine release

Botulism results from exposure to botulinum neurotoxin.

The toxin acts presynaptically by blocking ACh release.

Loss of transmitter output impairs skeletal-muscle activation.

Functional site schematic

Motor-axon terminal

Synaptic cleft

Myofiber sarcolemma

Presynaptic ACh-release blockade

Slide 59 · Curare blocks acetylcholine receptors

Curare refers to plant-derived agents that antagonize the muscle ACh receptor.

This postsynaptic blockade can cause flaccid paralysis.

The historical use of curare helped define junction physiology.

Functional site schematic

Motor-axon terminal

Synaptic cleft

Myofiber sarcolemma

ACh receptors blocked

Slide 60 · Different mechanisms converge on impaired contraction

Disorder

Primary lesion

Shared consequence

AChR myasthenia

Antibody-mediated receptor depletion

Weak contraction signal

MuSK myasthenia

Receptor trafficking / clustering defect

Weak contraction signal

Lambert–Eaton

Presynaptic calcium-channel inhibition

Less ACh release

Congenital myasthenia

Inherited junction-protein dysfunction

Weak contraction signal

Botulism / curare

Release inhibition / receptor blockade

Weak contraction signal

Slide 61 · Case exercise: Fatigable ocular weakness

Clinical presentation

A patient reports fluctuating diplopia and ptosis, with worsening weakness during exertion and later in the day.

Which lesion location and immune mechanism best fit?

Teaching answer: Postsynaptic myasthenia gravis; Anti–ACh receptor antibodies are the most common mechanism, with anti-MuSK antibodies in a smaller group.

Slide 62 · Case exercise: Weakness improved by brief activity

Clinical presentation

A patient has limb weakness that improves transiently after a few seconds of activity; Rapidly repeated stimulation increases the muscle response.

What syndrome and associated condition deserve attention?

Teaching answer: Lambert–Eaton myasthenic syndrome; Evaluate its important association with malignancy, particularly small cell lung carcinoma.

Slide 63 · Case exercise: Infant weakness with variable drug response

Clinical presentation

A child has poor tone, eye-muscle weakness and breathing difficulty early in life; Genetic testing identifies a junction-protein defect.

What disease group and treatment caveat apply?

Teaching answer: Congenital myasthenic syndrome; The clinical course and response to acetylcholinesterase inhibitors depend on the specific mutation.

Slide 64 · Use the physiologic pattern to narrow the differential

Observed pattern

Mechanistic interpretation

Textbook exemplar

Ocular weakness with exertional fatigue

Postsynaptic receptor impairment

Myasthenia gravis

Limb weakness with facilitation

Presynaptic release impairment

Lambert–Eaton

Early-life weakness plus inherited protein defect

Genetic junction dysfunction

Congenital syndrome

ACh-release blockade after toxin exposure

Toxin-induced presynaptic impairment

Botulism

Slide 65 · Core distinctions to retain

Myasthenia gravis: Usually postsynaptic autoimmunity; Ocular involvement and fatigability are prominent.

Lambert–Eaton: Presynaptic calcium-channel antibodies; Brief facilitation and cancer association.

Congenital syndromes: Genetically heterogeneous defects with mutation-dependent responses.

Botulinum toxin and curare interrupt transmission on opposite sides of the cleft.

Slide 66 · Source and scope

Primary source: Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th ed. (2026).

Chapter 27: Peripheral Nerves and Skeletal Muscles; Diseases of the Neuromuscular Junction, pp. 1115–1116.

Sections incorporated: Myasthenia Gravis; Lambert–Eaton Myasthenic Syndrome; Congenital Myasthenic Syndromes; Disorders Caused by Toxins.

Original schematic illustrations and teaching comparisons are constructed from this text; no external clinical images or updated treatment guidelines were incorporated.